文献速递心律失常血脂与心血管预防

澳大利亚房颤低卒中风险患者中卒中风险评分的比较性能

Comparative performance of stroke risk scores in patients with atrial fibrillation with low stroke risk
RSS 订阅 · Open Heart

各评分标为低风险的比例从2.0%至50.9%不等,CHA2DS2-VA区分度最低(C统计量0.61,95%CI 0.60-0.61),ATRIA最佳(0.66,95%CI 0.66-0.67)。指南推荐的CHA2DS2-VA将部分中风险患者也归入低于治疗阈值的人群。

要点

  • CHA2DS2-VA评分区分度最低(C统计量0.61),ATRIA最高(0.66)。
  • 各评分标为低风险的比例差异大,从2.0%(Modified-CHADS2)到50.9%(ATRIA)。
  • CHA2DS2-VA中风险患者卒中发生率低于治疗阈值,需考虑本地化风险工具。

核心结论

  • 指南推荐的CHA2DS2-VA评分区分度最低,其中风险患者卒中发生率低于治疗阈值。
  • 应考虑开发并验证适用于澳大利亚人群的风险工具。

研究设计与样本

  • 基于人群的队列研究,使用新南威尔士州入院患者数据、国家死亡指数和药品福利计划数据库链接数据。
  • 纳入2003年7月至2021年1月首次因房颤住院且未使用口服抗凝药的患者,随访至少12个月。

主要发现

  • 12个月内3552例(1.6%)因缺血性卒中住院。
  • 各评分标为低风险的比例范围为2.0%(Modified-CHADS2)至50.9%(ATRIA)。
  • 各评分低风险组及CHA2DS2-VA中风险组均满足真正低风险定义(年缺血性卒中<0.9%)。
  • C统计量:CHA2DS2-VA为0.61(95%CI 0.60-0.61),ATRIA为0.66(95%CI 0.66-0.67)。

关键数值与推荐

  • 真正低风险定义为年缺血性卒中发生率<0.9%。

临床怎么用

  • 在澳大利亚房颤患者中,CHA2DS2-VA评分可能将部分中风险患者错误归为低风险,需谨慎用于口服抗凝决策。
  • ATRIA评分区分度相对较好,但整体C统计量仍 modest。
  • 建议开发并验证本地适用的风险工具以优化抗凝决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background Australian guidelines recommend the CHA 2 DS 2 -VA (congestive heart failure, hypertension, age ≥75 years (double weight), diabetes mellitus, previous stroke (double weight), vascular disease, age 65–74 years) score to identify patients with atrial fibrillation (AF) at low stroke risk who should avoid oral anticoagulation. Treatment thresholds were derived from heterogeneous international data, and alternate scores require validation in an Australian population. We evaluated whether existing stroke scores (CHADS 2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, previous stroke (double weight)), CHA 2 DS 2 -VA, ATRIA (anticoagulation and risk factors in atrial fibrillation) and Modified-CHADS 2 ) accurately identify truly low-risk patients in Australia. Methods We conducted a population-based cohort study using linked data from the New South Wales Admitted Patient Data Collection, the National Death Index and the Pharmaceutical Benefits Scheme databases. Oral anticoagulant-naïve patients with a first hospital admission for AF between July 2003 and January 2021 were included. Patients were followed for ≥12 months and classified into low-risk, intermediate-risk or high-risk categories for each score. ‘Truly low-risk’ was defined as annual ischaemic stroke incidence <0.9%. Predictive accuracy was assessed using the concordance-statistic. Results Among 224 451 eligible patients, 3552 (1.6%) were hospitalised for ischaemic stroke within 12 months. The proportion labelled low-risk ranged from 2.0% (Modified-CHADS 2 ) to 50.9% (ATRIA). Patients assigned low-risk using each score, and intermediate-risk with the CHA 2 DS 2 -VA score, met the definition of truly low-risk. Concordance-statistics were modest, with the weakest performing score being the CHA 2 DS 2 -VA score (0.61, 95% CI 0.60 to 0.61) and the best performing model being the ATRIA score (0.66, 95% CI 0.66 to 0.67). Conclusions The guideline-endorsed CHA 2 DS 2 -VA score showed the lowest discrimination, and patients classified as intermediate-risk using this score had stroke incidence below the treatment threshold. Strong consideration should be given to the development and validation of locally applicable risk tools.

来源:Open Heart,查看原文。版权归原作者所有。

引用

  1. Open Heart:Comparative performance of stroke risk scores in patients with atrial fibrillation with low stroke risk

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。